Skip to main content
Skip to footer

Future of RBM in Clinical Trials

Dr. Niraj Vyas

Associate Vice President and Head, TCS ADD Analytics and Insights

You have these already downloaded

We have sent you a copy of the report to your email again.

Next-gen technologies can impact the risk-based monitoring in clinical trials.

Considering the growing demands to get better and affordable treatment options, there needs to be a fundamental shift in drug development and specifically the clinical trials oversight processes to mitigate risks and reduce failures. The International Council for Harmonization (ICH) E6 R2 addendum has now provided guidelines for adaptation of risk-based approach to trial conduct and monitoring to implement mitigation strategies and key risk indicators for potential risks which might derail the conduct of the trial. However, with the changing landscape of drug development which includes novel therapies such as gene therapy, decentralized trials, wearable technologies, eSource, electronic health record interoperability, and implementation of AI ML algorithms, the future of risk-based approach towards managing clinical trials is going to be very different from what we see now.

Related reading

Transparent AI in Pharmacovigilance and its Importance

White Paper | 20 Oct 2022

Standardization of Data Transfer Agreements & Automation in EDC

White Paper | 28 Sep 2022

Smart Medication for Enabling Patient Centricity

video | 19 Sep 2022

Merck renews its regulatory compliance strategy

Case Studies | 22 Aug 2022